MARKET COMPOSITE
NDRA - ENDRA Life Sciences Inc7:59:50 PM 4/18/2024
Price
$0.23
+ 0.00 (1.13%)
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript March 28, 2024 ENDRA Life Sciences Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.36. NDRA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […]

    Q4 2023 ENDRA Life Sciences Inc Earnings Call

    ANN ARBOR, Mich., March 28, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

    ANN ARBOR, Mich., March 21, 2024--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate develo

    ANN ARBOR, Mich., February 27, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it has installed a TAEUS liver system at King's College Hospital NHS Foundation Trust (KCH) in London, one of the leading centers of excellence in the United Kingdom's National Health Service (NHS).

    ANN ARBOR, Mich., February 21, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), welcomes the adoption of the ICD-10 K76.0 code for the diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD). This pivotal update supports recent important advancements in the field of liver disease to underscore the increasing recognition of NAFLD's impact on global health by insurers and healthcare providers alike. ENDRA’s TAEUS system has received a CE mark

    ANN ARBOR, Mich., February 14, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology.

    ANN ARBOR, Mich., November 29, 2023--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No. 11828727 (the ‘727 patent) titled "Thermoacoustic Probe."

    ANN ARBOR, Mich., November 27, 2023--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will be participating in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference being held Thursday, December 7, 2023 at the New York Athletic Club in New York City. Management will be holding one-on-one meetings with investors.

    ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good day, and welcome to the ENDRA Life Sciences Third Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference […]